Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 104 results found since Jan 2013.

Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy
This technology comprises live, attenuated Salmonella strains as a delivery system for small interfering double-stranded RNA (siRNA)-based tumor therapy. The inventors' data provide the first convincing evidence that Salmonella can be used for delivering plasmid-based siRNAs into tumors growing in vivo. Claimed in the related patent application are methods of inhibiting the growth or reducing the volume of solid cancer tumors using the si-RNA constructs directed against genes that promote tumor survival and cancer cell growth. The Stat3-siRNAs carried by an attenuated S. typhimurium described in the application exhibit tum...
Source: NIH OTT Licensing Opportunities - January 9, 2009 Category: Research Authors: admin Source Type: research

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
CONCLUSION: Our findings suggest a potential combination approach for cancer immunotherapy using PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs and PLGA (antigen+adjuvant)-NPs as novel immune checkpoint silencing agents.PMID:35228265 | DOI:10.1136/jitc-2021-003928
Source: Cancer Control - March 1, 2022 Category: Cancer & Oncology Authors: Ji Eun Won Youngseon Byeon Tae In Wi Chan Mi Lee Ju Hyeong Lee Tae Heung Kang Jeong-Won Lee YoungJoo Lee Yeong-Min Park Hee Dong Han Source Type: research

Evaluation of a DoE based approach for comprehensive modelling of the effect of lipid nanoparticle composition on nucleic acid delivery
Biomaterials. 2023 May 15;299:122158. doi: 10.1016/j.biomaterials.2023.122158. Online ahead of print.ABSTRACTTherapeutic nucleic acids (TNAs) comprise an alternative to conventional drugs for cancer therapy. Recently, stable nucleic acid lipid particles (SNALPs) have been explored to deliver TNA efficiently and safely both in vitro and in vivo. Small interfering RNA (siRNA) and messenger RNA (mRNA) based drugs have been suggested for a wide range of pathologies, and their respective lipid nanoparticle (LNP) formulations have been optimised using a Design of Experiments (DoE) approach. However, it is uncertain as to whether...
Source: Biomaterials - May 27, 2023 Category: Materials Science Authors: Yue Qin Adam A Walters Nadia Rouatbi Julie Tzu-Wen Wang Hend Mohamed Abdel-Bar Khuloud T Al-Jamal Source Type: research

Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Recent studies have underscored the importance of memory T cells in mediating protective immunity against pathogens and cancer. Pharmacological inhibition of regulators that mediate T cell differentiation promotes the differentiation of activated CD8+ T cells into memory cells. Nonetheless, pharmacological agents have broad targets and can induce undesirable immunosuppressive effects. Here, we tested the hypothesis that aptamer-targeted siRNA inhibition of mTOR complex 1 (mTORC1) function in CD8+ T cells can enhance their differentiation into memory T cells and potentiate antitumor immunity more effectively than the pharma...
Source: Journal of Clinical Investigation - December 4, 2013 Category: Biomedical Science Authors: Alexey Berezhnoy, Iris Castro, Agata Levay, Thomas R. Malek, Eli Gilboa Source Type: research

Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cell–mediated Cytotoxicity
In conclusion, expression of Bcl-2, Bcl-xL, and Bax in pancreatic tumor cells determines sensitivity towards both Gem-mediated and CTL-mediated toxicity. Bcl-2 silencing could be exploited therapeutically in tumor vaccine approaches.
Source: Journal of Immunotherapy - March 19, 2015 Category: Allergy & Immunology Tags: Basic Studies Source Type: research

Cancers, Vol. 11, Pages 176: Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
d Therapeutic dendritic cell (DC) cancer vaccines rely on the immune system to eradicate tumour cells. Although tumour antigen-specific T cell responses have been observed in most studies, clinical responses are fairly low, arguing for the need to improve the design of DC-based vaccines. The incorporation of small interfering RNAs (siRNAs) against immunosuppressive factors in the manufacturing process of DCs can turn the vaccine into potent immune stimulators. Additionally, siRNA modification of ex vivo-expanded T cells for adoptive immunotherapy enhanced their killing potency. Most of the siRNA-targeted immune inhibit...
Source: Cancers - February 3, 2019 Category: Cancer & Oncology Authors: Mouldy Sioud Tags: Review Source Type: research

Immune-Modulation by the Human Respiratory Syncytial Virus: Focus on Dendritic Cells
This study is complemented by another report that found that hRSV infection induces significant expression of three miRNAs, namely hsa-miR-4448, hsa-miR-30a-5p, and hsa-miR-4634 in human DCs (104). Interestingly, this latter study also performed comparative analyses of miRNA profiles between DCs infected with hRSV and a related virus, namely the human metapneumovirus, and found that both viruses induced the expression of elevated levels of hsa-miR-4634. Elucidating the contribution of these miRNAs in DCs in response to hRSV remains to be determined. Dendritic Cell Phenotype and Migration Upon hRSV Infection in vivo Altho...
Source: Frontiers in Immunology - April 14, 2019 Category: Allergy & Immunology Source Type: research

Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
ConclusionThese findings strongly suggest that TMC-DS-L NPs loaded with siRNA could act as a novel tool in inhibiting the expression of immune checkpoints in the tumor microenvironment. Also, combination therapy based on inhibition of PD-1 and LAG3 in combination with DC vaccine is an effective method in treating cancer that needs to be further studied.
Source: Pharmaceutical Research - June 17, 2022 Category: Drugs & Pharmacology Source Type: research

Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine.
Abstract A reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, has been developed as a vaccine against various cancers. Here, we report an unexpected function of GV1001 as a cell-penetrating peptide (CPP). GV1001 was delivered into a variety of cells including various cancer cell lines and primary blood cells. Moreover, the delivered GV1001 was predominantly located in the cytoplasm of the cells, while a significantly higher proportion of TAT peptide was localized in the nucleus. Macromolecules such as proteins, DNA and siRNA, which were linked to GV1001 by direct covalent conjugation or n...
Source: Biomaterials - July 1, 2013 Category: Materials Science Authors: Lee SA, Kim BR, Kim BK, Kim DW, Shon WJ, Lee NR, Inn KS, Kim BJ Tags: Biomaterials Source Type: research

Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions
In conclusion, pegylated anti-E6 lipoplexes have demonstrated their efficiency to cross the cellular membrane and to release siRNA into the cytoplasm confirmed by final p53 protein production. Graphical abstract
Source: International Journal of Pharmaceutics - February 27, 2015 Category: Drugs & Pharmacology Source Type: research

Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21
Conclusions. Our results demonstrate that autocrine CCL19 negatively affects DC migratory potential toward CCL21, the potency difference between CCL19 and CCL21 being the underlying cause. CCL19 secretion level of in vitro matured DCs is an important indicator of DC vaccine homing potential.
Source: Cytotherapy - July 14, 2016 Category: Cytology Source Type: research